Balance Sheet
Cash Flow Statement
Beginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UNITED THERAPEUTICS (UTHR) Gains from Investment Securities: 2009-2024

Historic Gains from Investment Securities for UNITED THERAPEUTICS (UTHR) over the last 16 years, with Dec 2024 value amounting to $400.6 million.

  • UNITED THERAPEUTICS's Gains from Investment Securities fell 89.13% to $8.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $373.6 million, marking a year-over-year decrease of 3.19%. This contributed to the annual value of $400.6 million for FY2024, which is 20.48% up from last year.
  • As of FY2024, UNITED THERAPEUTICS's Gains from Investment Securities stood at $400.6 million, which was up 20.48% from $332.5 million recorded in FY2023.
  • UNITED THERAPEUTICS's Gains from Investment Securities' 5-year high stood at $400.6 million during FY2024, with a 5-year trough of $92.8 million in FY2020.
  • In the last 3 years, UNITED THERAPEUTICS's Gains from Investment Securities had a median value of $332.5 million in 2023 and averaged $336.3 million.
  • Its Gains from Investment Securities has fluctuated over the past 5 years, first dropped by 22.80% in 2020, then soared by 79.84% in 2022.
  • Yearly analysis of 5 years shows UNITED THERAPEUTICS's Gains from Investment Securities stood at $92.8 million in 2020, then skyrocketed by 65.19% to $153.3 million in 2021, then spiked by 79.84% to $275.7 million in 2022, then climbed by 20.60% to $332.5 million in 2023, then increased by 20.48% to $400.6 million in 2024.